아델릭스 (ARDX) 주가

아델릭스(ARDX)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.42 (+1.18%), 시가총액 $1.50B.

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

핵심 지표

• 현재가: $3.42 (+1.18%)
• 시가총액: $1.50B
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NAS

아델릭스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

아델릭스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 적극 매수 (4.6 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 10.12
• 순이익률: -13.58%
• 영업이익률: -34.71%

자주 묻는 질문